Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines.

[1]  C. Eccleston,et al.  Systematic review and meta-analysis of psychological therapies for children with chronic pain. , 2014, Journal of pediatric psychology.

[2]  P. Eckburg,et al.  Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia , 2012 .

[3]  B. Limbago,et al.  Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Mandell,et al.  Methicillin-Resistant Staphylococcus aureus and Community-Acquired Pneumonia: An Evolving Relationship , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Paterson,et al.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Kollef,et al.  Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Nassisi,et al.  Evidence-based guidelines for evaluation and antimicrobial therapy for common emergency department infections. , 2012, Emergency medicine practice.

[8]  Samuel M. Brown,et al.  Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department. , 2012, Annals of emergency medicine.

[9]  Jiaquan Xu,et al.  Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[10]  B. Cao,et al.  Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. , 2011, International journal of antimicrobial agents.

[11]  A. Akram,et al.  Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. Limbago,et al.  Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  S. Kaplan,et al.  Staphylococcus aureus Pneumonia in Children in the Era of Community-acquired Methicillin-resistance at Texas Children's Hospital , 2011, The Pediatric infectious disease journal.

[14]  Jianguo Tang,et al.  Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community‐acquired pneumonia , 2011, Respirology.

[15]  Ronald N. Jones,et al.  LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States , 2011, Antimicrobial Agents and Chemotherapy.

[16]  Samir N. Patel,et al.  Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada , 2011, Antimicrobial Agents and Chemotherapy.

[17]  C. Ginocchio.  Strengths and Weaknesses of FDA-Approved/Cleared Diagnostic Devices for the Molecular Detection of Respiratory Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Peterson.  Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Kristine M Hujer,et al.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Bartlett.  Diagnostic tests for agents of community-acquired pneumonia. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Brad Spellberg,et al.  Combating antimicrobial resistance: policy recommendations to save lives. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Peter Bacchetti,et al.  Effect of emergency department crowding on pneumonia admission care components. , 2011, The American journal of managed care.

[23]  H. D. Friedland,et al.  Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.

[24]  C. Fischer,et al.  Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[25]  Elizabeth A. Rechtsteiner,et al.  Ambulatory medical care utilization estimates for 2007. , 2011, Vital and health statistics. Series 13, Data from the National Health Survey.

[26]  J. Milanowski,et al.  FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.

[27]  C. Schumann,et al.  FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.

[28]  Y. Hsieh,et al.  A meta-analysis of point-of-care laboratory tests in the diagnosis of novel 2009 swine-lineage pandemic influenza A (H1N1). , 2011, Diagnostic microbiology and infectious disease.

[29]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  K. Krause,et al.  Evaluation of Pneumococci From the United States (USA) Pediatric Patients Isolated During the 2009 AWARE Program , 2011 .

[31]  You-ning Liu,et al.  Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease , 2010, Antimicrobial Agents and Chemotherapy.

[32]  T. File,et al.  Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  P. Duca,et al.  Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department , 2010, Emergency Medicine Journal.

[34]  M. J. Hall,et al.  National Hospital Discharge Survey: 2007 summary. , 2010, National health statistics reports.

[35]  Y. Shemer-Avni,et al.  Respiratory Viruses in Adults With Community-Acquired Pneumonia , 2010, Chest.

[36]  M. Wilcox,et al.  Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  A. Akram,et al.  Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis , 2010, Thorax.

[38]  Y. Loke,et al.  Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis , 2010, Thorax.

[39]  R. Daum,et al.  Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic , 2010, Clinical Microbiology Reviews.

[40]  F. Martínez Sagasti,et al.  Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. , 2010, JAMA.

[41]  G. Erdem,et al.  Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii , 2010, Pediatric Radiology.

[42]  T. File,et al.  Burden of Community-Acquired Pneumonia in North American Adults , 2010, Postgraduate medicine.

[43]  R. Lynfield,et al.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. , 2010, The Journal of infectious diseases.

[44]  S. Kaplan,et al.  Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children , 2010, Pediatrics.

[45]  Dominic E Dwyer,et al.  Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[46]  C. Reed,et al.  Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006–2007 , 2009, Epidemiology and Infection.

[47]  Samuel M. Brown,et al.  Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia* , 2009, Critical care medicine.

[48]  S. Weingart,et al.  Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. , 2009, Annals of emergency medicine.

[49]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[50]  D. Vinh,et al.  Linezolid: a review of safety and tolerability. , 2009, The Journal of infection.

[51]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  D. Farrell,et al.  Increase in Pneumococcus Macrolide Resistance, United States , 2009, Emerging infectious diseases.

[53]  A. Hidrón,et al.  Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. , 2009, Lancet. Infectious Diseases (Print).

[54]  T. Welte,et al.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.

[55]  Stefano Di Bartolomeo,et al.  Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED. , 2009, The American journal of emergency medicine.

[56]  Philip M Polgreen,et al.  Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. , 2009, Annals of emergency medicine.

[57]  M. Niederman,et al.  Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  S. Richter,et al.  Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  R. Balk.  SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia , 2009 .

[60]  J. Maurer.  Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia , 2009 .

[61]  B. Thiers.  Increased US Emergency Department Visits for Skin and Soft Tissue Infections, and Changes in Antibiotic Choices, During the Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus , 2009 .

[62]  K. Shimada,et al.  Antimicrobial susceptibility of pathogens isolated from more than 10 000 patients with infectious respiratory diseases: a 25-year longitudinal study , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[63]  E. Rackow.  Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[64]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[65]  C. Tanaseanu,et al.  Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. , 2008, Diagnostic microbiology and infectious disease.

[66]  G. Tillotson,et al.  Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. , 2008, The Journal of antimicrobial chemotherapy.

[67]  David J. Ecker,et al.  Ibis T5000: a universal biosensor approach for microbiology , 2008, Nature Reviews Microbiology.

[68]  M. Kollef,et al.  Pneumonia caused by methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[70]  A. Anzueto,et al.  A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.

[71]  R. Paoloni,et al.  Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia , 2008, Emergency Medicine Journal.

[72]  D. Talan,et al.  Diagnosis and Management of Pneumonia in the Emergency Department , 2008, Infectious Disease Clinics of North America.

[73]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[74]  L. Friedrich,et al.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.

[75]  P. Appelbaum.  Microbiology of antibiotic resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  A. Pakyz,et al.  The Utility of Hospital Antibiograms as Tools for Guiding Empiric Therapy and Tracking Resistance: Insights from the Society of Infectious Diseases Pharmacists , 2007, Pharmacotherapy.

[77]  Susan S. Huang,et al.  Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[78]  D. Rasko,et al.  Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005 , 2007, The Pediatric infectious disease journal.

[79]  F. Tenover,et al.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  John Stelling,et al.  Medical Microbiology: Analysis and Presentation of Cumulative Antibiograms: A New Consensus Guideline from the Clinical and Laboratory Standards Institute , 2007 .

[81]  T. Marrie,et al.  Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit: A Descriptive Study , 2007, Medicine.

[82]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  M. Pichichero,et al.  Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States , 2007, The Pediatric infectious disease journal.

[84]  Ronald N. Jones,et al.  Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program , 2007, Antimicrobial Agents and Chemotherapy.

[85]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[86]  C. Bridges,et al.  Severe Community-acquired Pneumonia Due to Staphylococcus aureus, 2003–04 Influenza Season , 2006, Emerging infectious diseases.

[87]  T. File.  Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[88]  M. Bonten,et al.  Impact of Rapid Detection of Viral and Atypical Bacterial Pathogens by Real-Time Polymerase Chain Reaction for Patients with Lower Respiratory Tract Infection , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[90]  M. M. van der Eerden,et al.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study , 2005, Thorax.

[91]  D. Talan,et al.  Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections , 2005, Emerging infectious diseases.

[92]  Rangarajan Sampath,et al.  Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[93]  N. Sopena,et al.  Multicenter study of hospital-acquired pneumonia in non-ICU patients. , 2005, Chest.

[94]  Mian Cai,et al.  Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  J. Gerberding,et al.  Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. , 2005, MMWR. Morbidity and mortality weekly report.

[96]  W. Thompson,et al.  The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  D. Low,et al.  Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 , 2003, Antimicrobial Agents and Chemotherapy.

[98]  S. Cammarata,et al.  Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies , 2003, Antimicrobial Agents and Chemotherapy.

[99]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[100]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[101]  Ronald N. Jones,et al.  Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. , 2002, Diagnostic microbiology and infectious disease.

[102]  A. Kelly,et al.  Venous pH can safely replace arterial pH in the initial evaluation of patients in the emergency department , 2001, Emergency medicine journal : EMJ.

[103]  Inger,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[104]  I. Suramo,et al.  High-resolution computed tomography for the diagnosis of community-acquired pneumonia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  M. Niederman,et al.  The cost of treating community-acquired pneumonia. , 1998, Clinical therapeutics.

[106]  G. Jackson.  Infectious Diseases Society of America, Incorporated , 1971 .